SecBot SecBot
8-K ·Filed Apr 10, 2026

VIR

Vir Biotechnology, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago SEC0001193125-26-151209
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for updates on the CMO search and any interim leadership assignments, particularly given Vir's focus on clinical-stage biologics. The departure may prompt investor questions about continuity in medical strategy.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$9.31
T+0 close · Apr 10, 2026 · via day close
Latest settled
+12.03%
T+60 · $10.43
Vs SPY
+3.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $9.31entry
  2. T+1 · 7mo ago +7.95%α +6.74% · $10.05
  3. T+5 · 7mo ago +19.12%α +15.82% · $11.09
  4. T+20 · 6mo ago −0.21%α −7.94% · $9.29
  5. T+60 · 4mo ago +12.03%α +3.11% · $10.43
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vir Biotechnology's Chief Medical Officer, Mark Eisner, is stepping down effective April 24, 2026, and the company has begun a search for his successor. This is a C-suite departure but no immediate replacement was named.

Key Facts

  • Dr. Mark Eisner, Executive Vice President and Chief Medical Officer, is stepping down effective April 24, 2026.
  • He informed the company of his departure on April 7, 2026.
  • The company has initiated a search for a successor but has not named an interim or permanent replacement.
  • No reason for departure was specified beyond 'stepping down'.

Financial Impact

No direct financial impact disclosed; potential for near-term operational uncertainty in clinical development leadership.

leadership stabilityR&D oversight

Risk Factors

  • Potential disruption in clinical development leadership during transition
  • Increased scrutiny on management stability given recent insider selling

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-151209
Document: 0001193125-26-151209-index-headers.html0001193125-26-151209
Document: 0001193125-26-151209-index.html0001193125-26-151209
Document: 0001193125-26-151209.txt0001193125-26-151209

Track record

36 reports on VIR

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
  3. Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
  4. Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
  5. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
  6. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
  7. Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
  8. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
  10. Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (9h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 10, 2026